BostonGene to Showcase its Multimodal AI Platform Advancing Drug Development at the 2025 ASCO
BostonGene will showcase the impact of its validated, multimodal AI platform, which combines deep molecular profiling, immune system characterization and advanced analytics to accelerate and de-risk oncology drug development.
Share
BostonGene will showcase the impact of its validated, multimodal AI platform, which combines deep molecular profiling, immune system characterization and advanced analytics to accelerate and de-risk oncology drug development. Across six accepted studies—conducted independently and in collaboration with leading academic institutions—BostonGene will demonstrate how its platform uncovers novel biomarkers, refines patient stratification and predicts therapeutic response across a range of tumor types. Presentations will highlight advancements in transcriptomic analysis, immune microenvironment profiling, histomolecular subtyping and blood-based predictors—key tools for improving clinical trial design and driving precision treatment strategies.
Details about the abstracts selected for presentation can be found below:
Abstract number: 11536
Title: Molecular subtyping and insights into sarcoma biology and prognosis
Date & time: May 31 | 9:00 AM - 12:00 PM
Presenter: Nikita Kotlov, BostonGene
In this study, BostonGene's multiomic Tumor Portrait TM test was used to identify distinct molecular patterns in various sarcoma subtypes that correlated with survival outcomes. These findings demonstrate the potential clinical impact of advanced analytics paired with molecular sequencing in diverse diseases such as sarcoma.
Abstract number: 1049
Title: Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes
Date & time: June 2 | 9:00 AM - 12:00 PM
Presenter: Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center
In collaboration with MD Anderson, BostonGene used its advanced analytic platform to identify unique histologic and molecular findings in invasive lobular carcinoma (ILC), a subtype of breast cancer for which treatment options are often inferred. Profiling of over 600 patients resulted in the discovery of biologic mechanisms and alterations that could direct future therapeutic and drug development strategies.
Research done in collaboration with MD Anderson Cancer Center
Abstract number: 11561
Title: Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing
Date & time: May 31 | 9:00 AM - 12:00 PM
Presenter: Lev Bedniagin, MD, BostonGene
Leveraging BostonGene's extensive internal cohort and advanced sequencing technologies, this study conducted transcriptome analysis of Liposarcoma (LPS) samples, revealing novel hotspots of gene fusions in LPS patients. These discoveries can be used to improve diagnostic accuracy and the development of novel therapeutics in LPS and similar diseases.
Abstract number: 4198
Title: Uncovering the Tumor Microenvironment (TME): Exploring survival and immunotherapy (IO) response in Cancer of Unknown Primary (CUP)
Date & time: May 31 | 9:00 AM - 12:00 PM
Presenter: Joelle Allam, MD, The Texas University MD Anderson Cancer Center
In this study, BostonGene utilized its Tumor Portrait TM test to characterize Cancer of Unknown Primary (CUP). The analysis revealed correlations of clinical factors, the tumor microenvironment and immunotherapy response with survival outcomes, offering new insights into this challenging and poorly defined cancer.
Abstract number: 2634
Title: Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer
Date & time: June 2 | 1:30 PM - 4:30 PM
Presenter: Lev Bedniagin, MD, BostonGene
Leveraging BostonGene's AI-driven Kassandra deconvolution algorithm to analyze transcriptomic data from patients with non-small cell lung cancer, this study identified unique tertiary lymphoid structures within the tumor microenvironment that may serve as predictive and prognostic biomarkers, enhancing the efficacy of immune checkpoint inhibitor therapy.
This study demonstrated the clinical utility of the BostonGene Tumor Portrait TM test in guiding treatment selection for castrate-resistant prostate cancer based on tumor microenvironment-related gene signatures. These findings underscore the importance of precision medicine in managing cancer subtypes that are resistant to traditional interventions.
For more information, please visit the 2025 ASCO Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.
About BostonGene Corporation
BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 hours ago
- Business Wire
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
a day ago
- Business Wire
CUPE: Liberals reward Air Canada's refusal to bargain fairly by crushing flight attendants' Charter rights
TORONTO--(BUSINESS WIRE)--Air Canada asked the government to crush underpaid flight attendants' Charter rights, and Jobs Minister Patty Hajdu only waited a few hours to deliver. The Liberal government has invoked Section 107 of the Canada Labour Code to end a strike by Air Canada flight attendants fighting to end unpaid work and poverty wages. "The Liberals have talked out of both sides of their mouths. They said the best place for this is at the bargaining table. They refused to correct this historic injustice through legislation," said Wesley Lesosky, President of the Air Canada Component of CUPE. "Now, when we're at the bargaining table with an obstinate employer, the Liberals are violating our Charter rights to take job action and give Air Canada exactly what they want — hours and hours of unpaid labour from underpaid flight attendants, while the company pulls in sky-high profits and extraordinary executive compensation." CUPE came to the table with data-driven and reasonable proposals for a fair cost-of-living wage increase and an end to forced unpaid labour. Air Canada responded by sandbagging the negotiations. The Liberal government is rewarding Air Canada's refusal to negotiate fairly by giving them exactly what they wanted. This sets a terrible precedent. Contrary to the Minister's remarks, this will not ensure labour peace at Air Canada. This will only ensure that the unresolved issues will continue to worsen by kicking them down the road. Nor will it ensure labour peace in this industry — because unpaid work is an unfair practice that pervades nearly the entire airline sector, and will continue to arise in negotiations between flight attendants and other carriers.
Business Wire
a day ago
- Business Wire
'This government is anti-union and anti-worker': CUPE NS Denounces Use of Bill 107
HALIFAX, Nova Scotia--(BUSINESS WIRE)--CUPE Nova Scotia strongly condemns the federal government's decision to interfere in workers' right to collective bargaining and job action by invoking Section 107 of the Canada Labour Code. 'Clearly, this government is anti-union and anti-worker,' said Alan Linkletter, CUPE Nova Scotia President. 'Forcing workers back on the job instead of supporting free and fair collective negotiations directly contradictions workers' rights that are guaranteed under the Canadian Charter of Rights and Freedoms.' Air Canada has asked the government to crush striking workers' Charter rights, and Federal Labour minister Patty Hajdu is ready to deliver. Hajdu announced that the federal government will be invoking Section 107 at a press conference this afternoon, citing the financial welfare of Canadians and the economy at large as a deciding factor for this decision. 'She says this move is for the financial security of Canadians—are these workers not Canadians? Does their welfare not matter? How can you be financially secure when you don't even get paid for all of the hours you work?' Contrary to the Minister's remarks, this will not ensure labour peace in Canada. This will only push this fight onto the next group of workers in negotiations, while Air Canda's flight attendants continue to work for a billion-dollar company for free. Flight attendants are only paid when the plane is moving, and work as many as 35 unpaid hours a month performing vital duties that ensure the safe and smooth operation of each flight. Now, instead of paying flight attendants for all the hours they work, Air Canada has clearly sought help from the federal government to continue exploiting their employees. 'Minister Hajdu's comments indicate a clear lack of respect for workers' rights,' said Sherry Hillier, President of CUPE Newfoundland and Labrador and National General Vice President for Atlantic Canada. 'By using Section 107 to force workers back on the job yet again, they're setting a pattern. And that pattern is that Liberals don't care about Canadians.' Recent polling data indicates that 9 out of 10 Canadians support Air Canada flight attendants' fight for fair pay. 88% per cent of Canadians believe flight attendants should be paid for all work-related duties including boarding, delays, and safety checks. 76% support raising their pay to reflect the important safety role they play. 59% believe the federal government should respect flight attendants' right to take job action–even if it causes travel disruptions. CUPE represents over 10,000 Air Canada flight attendants across the country, and workers have been demonstrating at Halifax Stanfield International Airport since 6AM. 'Messages of support have been pouring in for these workers from across the country,' continued Linkletter. 'Canadians stand with us. Our elected representatives should, too.'
